Here’s How Much Canopy Growth Stock (TSX:WEED) Will Get on U.S. Legalization

Canopy Growth stock (TSX:WEED)(NYSE:CGC) climbed then fell back yet again last week, all amidst its continued U.S. expansion plans.

| More on:

Canopy Growth (TSX:WEED)(NYSE:CGC) continues to be on a wild ride that many investors have decided they want to get off. The company traded around $70 per share just a year ago, and yet today those shares have absolutely collapsed. At $16.38 as of writing, those all-time highs are now down by 77%.

Much of this comes from the collapse of cannabis in general, but it’s a bit worse for Canopy Growth stock. The company was on an acquisition spree before the pandemic. Now, it looks to be revving its engines once more. So let’s take a look at what Canopy Growth stock really hopes to accomplish with legalization in the United States.

Profitable moves

The issue before the pandemic was making a profit, which remains true today. However, Canopy Growth stock has made several moves in the past year toward this goal. The company kicked out founder and chief executive officer Bruce Linton back in 2019, with David Klein taking the reigns back in January 2020.

Luckily, much of the restructuring actually happened before the pandemic. Basically, Linton had tried to move too big, too fast. Significant losses came down as the company tried to expand its greenhouses to an unsupportable level. Combined with slow sales, it created a poor position for the Canopy Growth stock.

During the pandemic, production and acquisitions came to a standstill. Even with major partnerships with Constellation Brands, the company had to let hundreds of employees go.

But now, things are changing. It looks like Klein believes Canopy Growth stock can expand once more. So let’s see what exactly he has in mind.

U.S. expansion

To be clear, Canopy Growth stock is a Canadian company and also has overseas expansion. But the big one can’t be denied to be U.S. expansion. The U.S. market will be the largest consumer of cannabis in the world upon federal legalization. And don’t be fooled. That will eventually come. The real question is when?

But, if you’re a long-term holder, that answer shouldn’t bother you all that much. Instead, you want to invest in the company that could stand to make the most. So, is that Canopy Growth stock?

Canopy Growth stock has made a laundry list of acquisitions in the past few years set to come online upon legalization. In statement after statement, it says upon legalization the company will purchase 100% of shares in company after company.

This includes Acreage Holdings for US$3.4 billion, a recent deal with Wana Brands for US$297.5 million announced last week, and Supreme Cannabis earlier this year at $435 million.

If investors looked back (don’t worry, I did it for you), the company will spend at least $6 billion should all of its United States expansion plans come to fruition. This includes acquisitions, and also strategic investments in the hemp field to help the expansion.

However, this number does not include everything. Some releases didn’t actually state the purchase price. So it’s unclear how much the company is spending.

How much does it have on hand?

During its latest earnings report, Canopy Growth stock announced 23% year-over-year revenue growth. That number? $136.2 million for the quarter — not even a fraction of its future investment. Net income was a loss of $390 million, with adjusted EBITDA at a loss of $63.6 million.

Numbers are improving, but until legalization happens, they will continue to not improve by much. Despite having the number one market share in Canada, that’s peanuts compared to the United States. And Canopy Growth stock knows that.

The company maintains that achieving profitability is its top priority. And granted, its partnership with Constellation certainly helps these investments. The company’s cash and short-term investments sit at $2.1 billion during the last quarter. So the company does have some cash on hand to help pay down this eventual debt load.

So if you’re invested in Canopy Growth stock (as I am, you’ll notice), you’re in it for the long haul. But if you’re looking to buy, I’d hold off until some light appears through the smoke.

Fool contributor Amy Legate-Wolfe owns shares of Canopy Growth Corp. The Motley Fool has no position in any of the stocks mentioned.

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A cannabis plant grows.
Cannabis Stocks

These Threats Facing Canopy Growth Stock Could Justify Selling it

Let's dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip…

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »